North China Pharmaceuticals increase operating income and total profit by 107% and 40%

The Hebei-based company is the only one in China which commercially uses three expression systems (mammalian cells, recombinant yeast, Escherichia coli). They are a leading producer of hepatitis B vaccine, G-CSF, GM-CSF, EPO and are the country’s major producer of recombinant human serum albumin. Currently a number of antibodies, fusion proteins, cytokines, vaccines and other recombinant protein drugs are under development.

China Bio news release, February 23, 2018

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year. Accept or Deny